Newborn Screening for Pompe Disease

Pompe disease, also known as acid maltase deficiency or acid alpha-glucosidase deficiency, in its most severe form results in a rapidly progressive, neonatal-onset skeletal and cardiomyopathy, leading to early infantile death without treatment. The development of treatment with recombinant enzyme re...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Materialtyp: Online
Språk:engelska
Utgiven: MDPI - Multidisciplinary Digital Publishing Institute 2022
Ämnen:
Länkar:ONIX_20220111_9783036505800_316
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!
_version_ 1869517723675918336
collection Directory of Open Access Books
description Pompe disease, also known as acid maltase deficiency or acid alpha-glucosidase deficiency, in its most severe form results in a rapidly progressive, neonatal-onset skeletal and cardiomyopathy, leading to early infantile death without treatment. The development of treatment with recombinant enzyme replacement therapy radically transformed the clinical trajectory of those affected, enabling long-term ventilator-free survival with resolution of cardiomyopathy. These positive clinical outcomes resulted in the implementation of newborn screening programs for Pompe disease across the world. This Special Issue highlights some of the experiences of Pompe screening programs worldwide and discusses public policy and ethical issues elicited by presymptomatic screening for Pompe disease.
format Online
id doab-20.500.12854ir-76581
institution Directory of Open Access Books
language eng
publishDate 2022
publishDateRange 2022
publishDateSort 2022
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-765812024-04-09T23:16:30Z Newborn Screening for Pompe Disease Hwu, Wuh-Liang Chien, Yin-Hsiu Wang, Raymond Pompe disease newborn screening diagnosis infantile onset Pompe disease late onset Pompe disease patient perspective n/a California follow-up pseudodeficiency late-onset infantile-onset presymptomatic c.-32-13T&amp gt G infantile-onset Pompe disease GAA sequencing immune modulation therapy enzyme replacement therapy cross-reactive immunologic material genotype-phenotype correlation treatment and follow-up lysosomal storage diseases variant cut-off next generation sequencing dried blood spots new disorders implementation acid α-glucosidase alpha glucosidase Pompe disease diagnostics testing thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues Pompe disease, also known as acid maltase deficiency or acid alpha-glucosidase deficiency, in its most severe form results in a rapidly progressive, neonatal-onset skeletal and cardiomyopathy, leading to early infantile death without treatment. The development of treatment with recombinant enzyme replacement therapy radically transformed the clinical trajectory of those affected, enabling long-term ventilator-free survival with resolution of cardiomyopathy. These positive clinical outcomes resulted in the implementation of newborn screening programs for Pompe disease across the world. This Special Issue highlights some of the experiences of Pompe screening programs worldwide and discusses public policy and ethical issues elicited by presymptomatic screening for Pompe disease. 2022-01-11T13:36:09Z 2022-01-11T13:36:09Z 2021 book ONIX_20220111_9783036505800_316 9783036505800 9783036505817 https://directory.doabooks.org/handle/20.500.12854/76581 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4026 https://mdpi.com/books/pdfview/book/4026 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-0581-7 10.3390/books978-3-0365-0581-7 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036505800 9783036505817 146 Basel, Switzerland open access
spellingShingle Pompe disease
newborn screening
diagnosis
infantile onset Pompe disease
late onset Pompe disease
patient perspective
n/a
California
follow-up
pseudodeficiency
late-onset
infantile-onset
presymptomatic
c.-32-13T&amp
gt
G
infantile-onset Pompe disease
GAA sequencing
immune modulation therapy
enzyme replacement therapy
cross-reactive immunologic material
genotype-phenotype correlation
treatment and follow-up
lysosomal storage diseases
variant cut-off
next generation sequencing
dried blood spots
new disorders implementation
acid α-glucosidase
alpha glucosidase
Pompe disease diagnostics testing
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues
Newborn Screening for Pompe Disease
title Newborn Screening for Pompe Disease
title_full Newborn Screening for Pompe Disease
title_fullStr Newborn Screening for Pompe Disease
title_full_unstemmed Newborn Screening for Pompe Disease
title_short Newborn Screening for Pompe Disease
title_sort newborn screening for pompe disease
topic Pompe disease
newborn screening
diagnosis
infantile onset Pompe disease
late onset Pompe disease
patient perspective
n/a
California
follow-up
pseudodeficiency
late-onset
infantile-onset
presymptomatic
c.-32-13T&amp
gt
G
infantile-onset Pompe disease
GAA sequencing
immune modulation therapy
enzyme replacement therapy
cross-reactive immunologic material
genotype-phenotype correlation
treatment and follow-up
lysosomal storage diseases
variant cut-off
next generation sequencing
dried blood spots
new disorders implementation
acid α-glucosidase
alpha glucosidase
Pompe disease diagnostics testing
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues
topic_facet Pompe disease
newborn screening
diagnosis
infantile onset Pompe disease
late onset Pompe disease
patient perspective
n/a
California
follow-up
pseudodeficiency
late-onset
infantile-onset
presymptomatic
c.-32-13T&amp
gt
G
infantile-onset Pompe disease
GAA sequencing
immune modulation therapy
enzyme replacement therapy
cross-reactive immunologic material
genotype-phenotype correlation
treatment and follow-up
lysosomal storage diseases
variant cut-off
next generation sequencing
dried blood spots
new disorders implementation
acid α-glucosidase
alpha glucosidase
Pompe disease diagnostics testing
thema EDItEUR::T Technology, Engineering, Agriculture, Industrial processes::TB Technology: general issues
url ONIX_20220111_9783036505800_316